Bipolar Depression Licence Application For Seroquel(R)
AstraZeneca has submitted an application to the Medicines and Healthcare products Regulatory Agency (MHRA) for a new licence for Seroquel(R) (quetiapine fumarate) in the UK for major depressive episodes in the framework of bipolar disorder. Quetiapine is currently licensed in the UK for the treatment of schizophrenia and manic episodes associated with bipolar disorder.1 Bipolar disorder affects about one in every 100 adults at some point in their life.
Original post by Dentistry News From Medical News Today
Related Articles
Astrazeneca Submits Seroquel XR For The Treatment Of Bipolar Mania And Bipolar Depression, And Seroquel(R) For The Treatment Of Bipolar Depression Astrazeneca Submits Supplemental New Drug Applications For Seroquel XR For The Treatment Of Bipolar Mania And Bipolar Depression New Analysis Highlights Potential Of SEROQUEL For expanded-term Treatment Of Bipolar Disorder Cannabis Spray Licence Application Withdrawn, UK SEROQUEL Exhibits Distinct Mechanism Of Action And Reduces The Risk Of A Mood Event In Bipolar I Disorder
No comments yet. Be the first.
Leave a reply
